CIPLA
|
CIPLA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 34.71 | 31.19 | 29.82 | 19.18 | 18.96 |
| CEPS(Rs) | 49.65 | 44.76 | 43.02 | 33.76 | 35.20 |
| DPS(Rs) | 8.50 | 5.00 | 5.00 | 4.00 | 3.00 |
| Book NAV/Share(Rs) | 289.24 | 257.78 | 226.73 | 194.85 | 185.62 |
| Tax Rate(%) | 29.79 | 26.73 | 27.01 | 28.98 | 27.39 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.13 | 15.18 | 15.05 | 11.72 | 12.95 |
| EBIT Margin(%) | 13.41 | 12.11 | 12.22 | 8.76 | 9.40 |
| Pre Tax Margin(%) | 13.05 | 11.75 | 11.66 | 8.03 | 8.70 |
| PAT Margin (%) | 9.17 | 8.61 | 8.51 | 5.70 | 6.31 |
| Cash Profit Margin (%) | 12.95 | 12.15 | 12.29 | 10.03 | 11.86 |
| Performance Ratios | |||||
| ROA(%) | 10.19 | 9.94 | 9.95 | 6.56 | 6.50 |
| ROE(%) | 12.85 | 13.10 | 14.13 | 10.09 | 10.37 |
| ROCE(%) | 18.19 | 17.24 | 17.85 | 12.53 | 11.94 |
| Asset Turnover(x) | 1.11 | 1.15 | 1.17 | 1.15 | 1.03 |
| Sales/Fixed Asset(x) | 1.81 | 1.82 | 1.85 | 1.89 | 1.79 |
| Working Capital/Sales(x) | 2.63 | 3.03 | 3.29 | 3.71 | 2.76 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.55 | 0.55 | 0.54 | 0.53 | 0.56 |
| Receivable days | 44.13 | 42.19 | 47.44 | 54.10 | 55.36 |
| Inventory Days | 61.98 | 61.53 | 58.49 | 56.12 | 61.13 |
| Payable days | 109.80 | 98.28 | 107.95 | 128.84 | 128.32 |
| Valuation Parameters | |||||
| PER(x) | 25.95 | 32.65 | 27.34 | 22.05 | 27.91 |
| PCE(x) | 18.14 | 22.75 | 18.95 | 12.53 | 15.04 |
| Price/Book(x) | 3.11 | 3.95 | 3.60 | 2.17 | 2.85 |
| Yield(%) | 0.94 | 0.49 | 0.61 | 0.95 | 0.57 |
| EV/Net Sales(x) | 3.15 | 3.72 | 3.45 | 2.10 | 2.83 |
| EV/Core EBITDA(x) | 13.02 | 16.77 | 14.63 | 10.12 | 12.97 |
| EV/EBIT(x) | 17.27 | 22.52 | 19.16 | 15.12 | 20.62 |
| EV/CE(x) | 2.47 | 3.04 | 2.66 | 1.53 | 1.95 |
| M Cap / Sales | 3.19 | 3.78 | 3.43 | 1.99 | 2.61 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 4.55 | 13.59 | 11.84 | 4.70 | 7.96 |
| Core EBITDA Growth(%) | 13.83 | 6.98 | 27.27 | -0.66 | 12.24 |
| EBIT Growth(%) | 15.23 | 4.31 | 45.26 | 5.69 | 26.01 |
| PAT Growth(%) | 10.78 | 6.59 | 55.23 | 2.48 | 6.36 |
| EPS Growth(%) | 11.28 | 4.61 | 55.46 | 1.16 | 8.23 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.04 | 0.10 | 0.18 | 0.29 |
| Current Ratio(x) | 3.34 | 2.99 | 2.87 | 2.66 | 3.29 |
| Quick Ratio(x) | 2.31 | 1.91 | 1.85 | 1.67 | 2.24 |
| Interest Cover(x) | 37.87 | 33.85 | 21.47 | 12.04 | 13.34 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | 0.03 | 0.08 | 0.10 |
Compare Financial Ratios of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹112,983.5 Cr | 3.5% | 4.2% | 51.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹367,470.0 Cr | -0.9% | 0.9% | 62.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹105,846.0 Cr | 12.2% | 18% | 103.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹103,849.0 Cr | 0.8% | 5.6% | 19.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,742.1 Cr | -1% | -2.4% | 28.4% | Stock Analytics | |
| MANKIND PHARMA | ₹83,873.0 Cr | -6.1% | -11.9% | 54.1% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 3.5% |
4.2% |
51.8% |
| SENSEX | 1.7% |
0.7% |
19.2% |
You may also like the below Video Courses
